Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Vanda Pharmaceuticals Inc. has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 distinct examiners and 7 distinct art units, reflecting broad prosecution activity across several examination groups and many examiner relationships.
WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 2 pending matters. The modest concentration around the busiest examiner means the portfolio requires coordination across multiple prosecution channels rather than reliance on one examiner dialogue.
The difference between the action, examiner, and art-unit counts shows that some examiners and units handle more than one matter. Counsel can use those recurring assignments to compare claim treatment and prior-art issues, while maintaining matter-specific response positions.
For portfolio management, shared biotechnology terminology and disclosure support should be reviewed across the unit groupings. Examiner-specific analysis remains important because the assignments are not consolidated under a single reviewer.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 2 (18%) |
| §102 only | 1 (9%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 4 (36%) |
| Multi-statute (no §101) | 2 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 2 | 62.4% | +24.3% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565752 | METHODS OF SLOWING AN INCREASE IN BRAIN VENTRICULAR VOLUME | SAEED, KAMAL A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629598 | DEPOT ADMINISTRATION OF ILOPERIDONE | HELM, CARALYNNE E | 42d overdue |
| 18527638 | TREATMENT OF ACUTE ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR | KUCKLA, ANNA GRACE | 5d overdue |
| 18839564 | TRICHOSTATIN A (TSA) SENSITIVITY IN THE TREATMENT OF TUMORS | WHITE, DAWANNA SHAR-DAY | — |
| 18578371 | Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment | TATGE, LEXUS MARC | — |
| 18565690 | METHODS FOR TREATING MULTIPLE SCLEROSIS | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629598 | DEPOT ADMINISTRATION OF ILOPERIDONE | HELM, CARALYNNE E | 42d overdue |
| 18527638 | TREATMENT OF ACUTE ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR | KUCKLA, ANNA GRACE | 5d overdue |
| 18249920 | TREATMENT OF PUBLIC SPEAKING ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST | WHITE, DAWANNA SHAR-DAY | 27d |
| 18839564 | TRICHOSTATIN A (TSA) SENSITIVITY IN THE TREATMENT OF TUMORS | WHITE, DAWANNA SHAR-DAY | — |
| 18754070 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | RAMACHANDRAN, UMAMAHESWARI | — |
| 18652776 | USE OF TRADIPITANT IN MOTION SICKNESS | PIHONAK, SARAH | — |
| 18691426 | TREATMENT OF SLEEP DISTRUBANCES IN AUTISM SPECTRUM DISORDER PATIENTS | SZNAIDMAN, MARCOS L | — |
| 18684397 | TREATMENT OF LOWER RESPIRATORY TRACT INFECTION WITH TRADIPITANT | CHEN, PO-CHIH | — |
| Art Unit | Apps |
|---|---|
| 1627 | 4 |
| 1626 | 2 |
| 1615 | 1 |
| 1628 | 1 |
| 1621 | 1 |
| 1637 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839564 | TRICHOSTATIN A (TSA) SENSITIVITY IN THE TREATMENT OF TUMORS | WHITE, DAWANNA SHAR-DAY | 1627 | §101§103DP | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18754070 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | RAMACHANDRAN, UMAMAHESWARI | 1627 | §112DP | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18652776 | USE OF TRADIPITANT IN MOTION SICKNESS | PIHONAK, SARAH | 1627 | §103DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18629598 | DEPOT ADMINISTRATION OF ILOPERIDONE | HELM, CARALYNNE E | 1615 | §103 | Non-Final OA | 42d overdue | Pending | Apr 08, 2024 |
| 18691426 | TREATMENT OF SLEEP DISTRUBANCES IN AUTISM SPECTRUM DISORDER PATIENTS | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18684397 | TREATMENT OF LOWER RESPIRATORY TRACT INFECTION WITH TRADIPITANT | CHEN, PO-CHIH | 1621 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18578371 | Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment | TATGE, LEXUS MARC | 1637 | §103DP | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18527638 | TREATMENT OF ACUTE ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR | KUCKLA, ANNA GRACE | 1626 | §102§103Other | Final Rejection | 5d overdue | Pending | Dec 04, 2023 |
| 18565690 | METHODS FOR TREATING MULTIPLE SCLEROSIS | GONZALEZ, LUISALBERTO | 1624 | §102§103 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18565752 | METHODS OF SLOWING AN INCREASE IN BRAIN VENTRICULAR VOLUME | SAEED, KAMAL A | 1626 | §102 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18249920 | TREATMENT OF PUBLIC SPEAKING ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | 27d | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVanda Pharmaceuticals Inc. has 11 pending office actions as of October 2026, spread across 7 art units and 10 examiners.
Dawanna Shar-Day White has the most, with 2 of Vanda Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
